Literature DB >> 22679559

Inflammation in thyroid oncogenesis.

Federica Liotti, Carla Visciano, Rosa Marina Melillo.   

Abstract

It is commonly accepted that cancer is linked to inflammation. The possible mechanisms by which inflammation can contribute to carcinogenesis include induction of genomic instability, alterations in epigenetic events and subsequent inappropriate gene expression, enhanced proliferation of initiated cells, resistance to apoptosis, aggressive tumor neovascularization, invasion through tumor-associated basement membrane and metastasis. Inflammation also affects immune surveillance and responses to therapy. In this review, we overview the current understanding of different aspects of thyroid cancer and inflammation. Several studies have strongly suggested an increased risk of PTC in patients with Hashimoto's thyroiditis (HT), the most common autoimmune disease in thyroid cancer. Furthermore, an intense immune infiltrate is often associated with papillary thyroid carcinoma (PTC), and might play a critical role in the regulation of carcinogenesis and in carcinoma progression. The characterization of the most relevant inflammatory pathways of cancer-related inflammation (CRI) is instrumental for the identification of new target molecules that could lead to improved diagnosis and treatment.

Entities:  

Keywords:  Cancer-related inflammation; chemokine; inflammatory cell; thyroid cancer

Year:  2012        PMID: 22679559      PMCID: PMC3365810     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  84 in total

1.  Proinflammatory mediators and genetic background in oncogene mediated tumor progression.

Authors:  John P Russell; Julie B Engiles; Jay L Rothstein
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

2.  Mast cells have a protumorigenic role in human thyroid cancer.

Authors:  R M Melillo; V Guarino; E Avilla; M R Galdiero; F Liotti; N Prevete; F W Rossi; F Basolo; C Ugolini; A de Paulis; M Santoro; G Marone
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

Review 3.  Dysfunction of the RET receptor in human cancer.

Authors:  M Santoro; F Carlomagno; R M Melillo; A Fusco
Journal:  Cell Mol Life Sci       Date:  2004-12       Impact factor: 9.261

4.  Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.

Authors:  B Belletti; P Ferraro; C Arra; G Baldassarre; P Bruni; S Staibano; G De Rosa; G Salvatore; A Fusco; M G Persico; G Viglietto
Journal:  Oncogene       Date:  1999-08-26       Impact factor: 9.867

Review 5.  Chemokines in cancer related inflammation.

Authors:  Paola Allavena; Giovanni Germano; Federica Marchesi; Alberto Mantovani
Journal:  Exp Cell Res       Date:  2010-12-04       Impact factor: 3.905

Review 6.  The GDNF/RET signaling pathway and human diseases.

Authors:  M Takahashi
Journal:  Cytokine Growth Factor Rev       Date:  2001-12       Impact factor: 7.638

7.  Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells.

Authors:  Shogo Shinohara; Jay L Rothstein
Journal:  Oncogene       Date:  2004-09-30       Impact factor: 9.867

8.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors:  Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

9.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

Authors:  R Donghi; A Longoni; S Pilotti; P Michieli; G Della Porta; M A Pierotti
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

10.  Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma.

Authors:  Clara Ugolini; Fulvio Basolo; Agnese Proietti; Paolo Vitti; Rossella Elisei; Paolo Miccoli; Antonio Toniolo
Journal:  Thyroid       Date:  2007-05       Impact factor: 6.568

View more
  22 in total

1.  How do etiological factors can explain the different clinical features of patients with differentiated thyroid cancer and their histopathological findings?

Authors:  Loredana Pagano; Chiara Mele; Debora Arpaia; Maria Teresa Samà; Marina Caputo; Serena Ippolito; Carmela Peirce; Flavia Prodam; Guido Valente; Giuseppe Ciancia; Gianluca Aimaretti; Bernadette Biondi
Journal:  Endocrine       Date:  2016-05-26       Impact factor: 3.633

2.  ER-alpha and ER-beta expression in differentiated thyroid cancer: relation with tumor phenotype across the TNM staging and peri-tumor inflammation.

Authors:  Flavia Magri; Valentina Capelli; Margherita Gaiti; Laura Villani; Francesca Zerbini; Luigi La Manna; Mario Rotondi; Luca Chiovato
Journal:  Endocrine       Date:  2014-10-22       Impact factor: 3.633

3.  Inflammatory mediators, tumor necrosis factor-α and interferon-γ, induce EMT in human PTC cell lines.

Authors:  Nannan Lv; Yun Gao; Haixia Guan; Dan Wu; Shuangning Ding; Weiping Teng; Zhongyan Shan
Journal:  Oncol Lett       Date:  2015-07-21       Impact factor: 2.967

4.  Significance of DMBT1 in Papillary Thyroid Carcinoma Concurrent With Hashimoto's Thyroiditis.

Authors:  Xiao-Xiong Gan; Ya-Yi Li; Si-Jin Li; Shi-Sen Mo; Jian-Hua Feng; Fei Shen; Wen-Song Cai; Ye-Qian Lai; Bo Xu
Journal:  Front Oncol       Date:  2021-08-04       Impact factor: 6.244

5.  The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.

Authors:  O Awwad; F Coperchini; P Pignatti; M Denegri; S Massara; L Croce; C A Di Buduo; V Abbonante; A Balduini; L Chiovato; M Rotondi
Journal:  J Endocrinol Invest       Date:  2018-03-15       Impact factor: 4.256

6.  The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.

Authors:  Pierre Vanden Borre; David G McFadden; Viswanath Gunda; Peter M Sadow; Shohreh Varmeh; Maria Bernasconi; Tyler Jacks; Sareh Parangi
Journal:  Thyroid       Date:  2014-01-24       Impact factor: 6.568

7.  RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Authors:  Robert C Smallridge; Ana-Maria Chindris; Yan W Asmann; John D Casler; Daniel J Serie; Honey V Reddi; Kendall W Cradic; Michael Rivera; Stefan K Grebe; Brian M Necela; Norman L Eberhardt; Jennifer M Carr; Bryan McIver; John A Copland; E Aubrey Thompson
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

8.  Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.

Authors:  Zeyu Yang; Li Yin; Yuhang Zeng; Yao Li; Hongdan Chen; Supeng Yin; Fan Zhang; Wang Yang
Journal:  Virchows Arch       Date:  2021-06-19       Impact factor: 4.064

Review 9.  The Role of Snail-1 in Thyroid Cancer-What We Know So Far.

Authors:  Katarzyna Wieczorek-Szukala; Andrzej Lewinski
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

10.  The role of chronic inflammation in obesity-associated cancers.

Authors:  Maria E Ramos-Nino
Journal:  ISRN Oncol       Date:  2013-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.